Answers are grounded in this paper and cite their sources.
Our results highlight high unmet needs of CKD and T2D, particularly subgroups of patients with multimorbid CVD, high-risk CKD (low estimated glomerular filtration rate or high urinary albumin:creatinine ratio) or rapidly progressing CKD. Low initiation and high discontinuation of recommended treatments suggest that adherence to guidelines for halting CKD progression is suboptimal. These high-risk patients may benefit from further treatment options to improve morbidity and mortality and reduce the economic burden.
No takes yet. Share an insight, caveat, or question.
Fried et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: